Provided by Tiger Trade Technology Pte. Ltd.

Arcus Biosciences Inc.

26.15
-2.3400-8.21%
Post-market: 26.150.00000.00%19:30 EDT
Volume:2.39M
Turnover:63.89M
Market Cap:3.33B
PE:-6.77
High:28.46
Open:28.02
Low:25.91
Close:28.49
52wk High:31.74
52wk Low:11.30
Shares:127.33M
Float Shares:89.84M
Volume Ratio:2.05
T/O Rate:2.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8641
EPS(LYR):-3.2900
ROE:-90.82%
ROA:-30.39%
PB:7.18
PE(LYR):-7.95

Loading ...

Arcus Biosciences Inc Expected to Post a Loss of 90 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Arcus Biosciences (RCUS) Expands Kidney Cancer Collaboration, Is The Stock Still Undervalued?

Simply Wall St.
·
Aug 03

Bank of America Securities Sticks to Their Hold Rating for Arcus Biosciences (RCUS)

TIPRANKS
·
Aug 03

BofA Securities Adjusts Arcus Biosciences Price Target to $29 From $25

MT Newswires Live
·
Aug 03

Earning Preview: Arcus Biosciences Inc. revenue is expected to decrease by 25.80% this quarter, and institutional views are largely cautious

Earnings Agent
·
Jul 29

Arcus Biosciences Grants New Hires Stock Options for 12,600 Shares at $29.73 Each

Reuters
·
Jul 28

Arcus Biosciences Announces Clinical Supply Agreement with Aveo Oncology

Reuters
·
Jul 23

Arcus Biosciences, Summit Therapeutics Team up to Test Casdatifan-ivonescimab Combo in Kidney Cancer

Reuters
·
Jul 23

Arcus Biosciences - Aveo to Supply Tivozanib; Arcus to Sponsor Study; Each Retains Rights to Compounds

THOMSON REUTERS
·
Jul 23

Arcus Biosciences - Enrollment for New Arc-20 Cohort Expected to Begin in Q4 2026

THOMSON REUTERS
·
Jul 23

Arcus Biosciences Inc: Initial Data from This Clinical Trial Collaboration is Expected to be Generated by Mid-2027

THOMSON REUTERS
·
Jul 23

Arcus Biosciences Inc: Both Cos Will Contribute to Cost of Study, Each Co Will Retain Development & Commercial Rights to Their Respective Molecules

THOMSON REUTERS
·
Jul 23

Arcus Biosciences Inc: Under Terms of Agreement, Summit Will Supply Ivonescimab and Arcus Will Conduct and Sponsor Combination Study

THOMSON REUTERS
·
Jul 23

Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

THOMSON REUTERS
·
Jul 23

Press Release: Arcus Biosciences to Host Conference Call to Discuss Second-quarter 2026 Financial Results and Pipeline Updates

Dow Jones
·
Jul 22

Arcus Biosciences Schedules Call on Second-quarter Financial Results and Pipeline Update

Reuters
·
Jul 22

Arcus Biosciences is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jul 20

Arcus Biosciences price target raised to $45 from $32 at H.C. Wainwright

TIPRANKS
·
Jul 20

Arcus Biosciences President Juan C. Jaen Disposes of $2.05 Million in Common Shares

Reuters
·
Jul 14

Arcus Biosciences Grants Inducement Stock Options for 16,060 Shares at $30.26 Each

Reuters
·
Jul 10